Compare NEO & BTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEO | BTZ |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 998.6M |
| IPO Year | 2008 | N/A |
| Metric | NEO | BTZ |
|---|---|---|
| Price | $7.90 | $10.02 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $11.14 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 307.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.41 |
| Revenue | N/A | N/A |
| Revenue This Year | $10.63 | N/A |
| Revenue Next Year | $9.73 | N/A |
| P/E Ratio | ★ N/A | $7.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $9.54 |
| 52 Week High | $13.74 | $11.18 |
| Indicator | NEO | BTZ |
|---|---|---|
| Relative Strength Index (RSI) | 19.28 | 17.83 |
| Support Level | $7.07 | N/A |
| Resistance Level | $8.89 | $10.84 |
| Average True Range (ATR) | 0.47 | 0.10 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 2.30 | 2.76 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Blackrock Credit Allocation Income Trust is a diversified, closed-end Trust engaged in providing investment advisory and risk management solutions. Its investment objective is to seek current income, current gains, and capital appreciation. The company invests under normal market conditions, at least 80% of its assets in credit-related securities, including, but not limited to, investment-grade corporate bonds, high-yields, bank loans, preferred securities or convertible bonds, or derivatives with economic characteristics similar to these credit-related securities.